CAS 25546-65-0: Ribostamycin
Description:Ribostamycin is an aminoglycoside antibiotic that is primarily used for its antibacterial properties. It is derived from the fermentation of certain actinomycetes and is known for its effectiveness against a range of Gram-positive and some Gram-negative bacteria. The compound exhibits a mechanism of action that involves binding to the bacterial ribosome, inhibiting protein synthesis, which ultimately leads to bacterial cell death. Ribostamycin is particularly noted for its activity against mycobacterial infections, making it a candidate for treating tuberculosis and other mycobacterial diseases. In terms of its chemical structure, Ribostamycin contains multiple amino groups and a sugar moiety, which contribute to its solubility and interaction with bacterial ribosomes. The substance is typically administered via injection, and its pharmacokinetics can vary based on the route of administration. As with many antibiotics, the potential for resistance development is a concern, necessitating careful use and monitoring in clinical settings.
Formula:C17H34N4O10
InChI:InChI=1S/C17H34N4O10/c18-2-6-10(24)12(26)8(21)16(28-6)30-14-5(20)1-4(19)9(23)15(14)31-17-13(27)11(25)7(3-22)29-17/h4-17,22-27H,1-3,18-21H2/t4-,5+,6-,7-,8-,9+,10-,11-,12-,13-,14-,15-,16-,17+/m1/s1
InChI key:InChIKey=NSKGQURZWSPSBC-VVPCINPTSA-N
SMILES:OCC1OC(OC2C(O)C(N)CC(N)C2OC3OC(CN)C(O)C(O)C3N)C(O)C1O
- Synonyms:
- (1R,2R,3S,4R,6S)-4,6-diamino-3-hydroxy-2-(beta-D-ribofuranosyloxy)cyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside
- (1R,3S,4R,6S)-4,6-diamino-3-hydroxy-2-(beta-D-ribofuranosyloxy)cyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside sulfate (salt)
- 4,6-Diamino-3-Hydroxy-2-(Pentofuranosyloxy)Cyclohexyl 2,6-Diamino-2,6-Dideoxyhexopyranoside
- <span class="text-smallcaps">D</smallcap>-Streptamine, O-2,6-diamino-2,6-dideoxy-α-<smallcap>D</smallcap>-glucopyranosyl-(1→4)-O-[β-<smallcap>D</span>-ribofuranosyl-(1→5)]-2-deoxy-
- Antibiotic SF 733
- Brn 1357280
- Bu 1709
- D-Streptamine, O-2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1-4)- O-(beta-D-ribofuranosyl-(1-5))-2-deoxy-
- D-Streptamine, O-2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1-4)-O-(beta-D-ribofuranosyl-(1-5))-2-deoxy- (8CI)(9CI)
- Dekamycin IV
- See more synonyms
- Hetangmycin
- Nsc 138925
- O-2,6-Diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1-4)-O-(beta-D-ribofuranosyl-(1-5))-2-deoxystreptamine
- O-2,6-Diamino-2,6-dideoxy-α-<span class="text-smallcaps">D</smallcap>-glucopyranosyl-(1→4)-O-[β-<smallcap>D</smallcap>-ribofuranosyl-(1→5)]-2-deoxy-<smallcap>D</span>-streptamine
- Ribastamin
- Ribostamicina
- Ribostamicina [INN-Spanish]
- Ribostamycin [INN:BAN]
- Ribostamycine
- Ribostamycine [INN-French]
- Ribostamycinum
- Ribostamycinum [INN-Latin]
- Sf 733
- Unii-2Q5Jou7T53
- Vistamycin
- Xylostatin
- Ribostamycin
- D-Streptamine, O-2,6-diamino-2,6-dideoxy-α-D-glucopyranosyl-(1→4)-O-[β-D-ribofuranosyl-(1→5)]-2-deoxy-
- Ribostamycin
- O-2,6-Diamino-2,6-dideoxy-α-D-glucopyranosyl-(1→4)-O-[β-D-ribofuranosyl-(1→5)]-2-deoxy-D-streptamine
Brand | Product data | Purity | Price range | Estimated delivery |
---|---|---|---|---|
![]() | Ribostamycin Sulfate REF: 3B-R0194CAS: | >90.0%(N) | 336.00 € | Fri 28 Mar 25 |
![]() | Ribostamycin REF: 4Z-R-130001CAS: 25546-65-0 | - - - | To inquire | Mon 07 Apr 25 |
![]() | Ribostamycin REF: TM-T74207CAS: 25546-65-0 | - - - | To inquire | Mon 07 Apr 25 |
![]() | Ribostamycin REF: 3D-ABA54665CAS: 25546-65-0 | Min. 95% | - - - | Discontinued product |

Ribostamycin Sulfate
Ref: 3B-R0194
1g | 336.00 € |

Ref: 4Z-R-130001
5mg | To inquire | ||
10mg | To inquire | ||
25mg | To inquire | ||
50mg | To inquire | ||
100mg | To inquire |

Ribostamycin
Ref: TM-T74207
5mg | To inquire | ||
50mg | To inquire |

Ribostamycin
Ref: 3D-ABA54665
1g | Discontinued | Request information | |
5g | Discontinued | Request information | |
10g | Discontinued | Request information | |
1mg | Discontinued | Request information | |
10mg | Discontinued | Request information | |
250mg | Discontinued | Request information | |
500mg | Discontinued | Request information |